Rapport Semestriel 2024

September 24, 2024 11:45 ET | Source: Transgene S.A. Transgene S.A.

Rapport Semestriel 2024

Pièce jointe

TRANSGENE_RAPPORT-FINANCIER-SEMESTRIEL-2024_FR

Tags

Half-Year Financial Results RAPPORT SEMESTRIEL

Attachments

TRANSGENE_RAPPORT-FINANCIER-SEMESTRIEL-2024_FR

TRANSGENE_RAPPORT-FINANCIER-SEMESTRIEL-2024_FR...

Recommended Reading

November 06, 2025 02:30 ET | Source: Transgene S.A.

Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines

Computational tool improves recombinant virus design efficiency and yield. This innovative in-house development is a key component of Transgene’s INTV1 platform. Poster to be presented at ESMO-AI...
Read More
November 04, 2025 11:50 ET | Source: Transgene S.A.

Transgene Provides Business and Financial Update for Q3 2025

Comprehensive immunogenicity data of individualized neoantigen therapeutic vaccine (INTV) TG4050, from the randomized Phase I study in operable Head and Neck Squamous Cell Carcinoma (HNSCC)...
Read More